Technology Bundle ID: TAB-2649

Novel Live-Attenuated Rabies Vaccine

Request More Info
Licensing Contact:
Primary Inventors: 
Xianfu Wu (CDC)
Co-Inventors: 
Charles Rupprecht (CDC)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 
CDC

The critical feature of this technology is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA sequence. With the availability of the entire rabies genome, a recombinant vaccine can be developed using reverse genetics. Using this technology, CDC researchers have developed a recombinant, live-attenuated vaccine shown to confer protection against lethal doses of live, street-rabies virus in multiple survival studies. This vaccine offers better protection than traditional inactivated vaccinations, as demonstrated in co-infection studies. Further, a single intramuscular vaccination with the CDC's attenuated-virus was sufficient for survival of 100% of hamsters and mice following lethal challenge.

Applications:
  • Rabies vaccine design and development
  • Immunogenic compositions for both prevention and treatment of rabies virus
  • Rabies virus research
Advantages:
  • Live attenuated vaccine shows greater efficacy than older inactivated vaccine
  • 100% animal survival conferred by a single inoculation before lethal challenge

Patents

PCT Application PCT/US2006/040134
Filed on 2006-10-13
US Application 60/727,038
Filed on 2005-10-14
US Pat 7,863,041

Issued 2011-01-04
US Pat 8,865,461

Issued 2014-10-21

Publications

Bankovskiy D, et al.
PMID 18634508
Franka R, et al.
PMID 21514343
Wu X, Rupprecht CE.
PMID 17850911
Wu X, et al.
PMID 17681631
Wu X, et al.
PMID 21514343

Updated

Sep 19, 2013

Data Source: 
tts